David Brent Carpenter

Address:

1324 Heatherloch Dr, Gastonia, NC 28054

VIN:

4T1BK3DB7BU410916

Make:

TOYOTA

Model:

AVALON

Year:

2011

US Patent:

20230000866, Jan 5, 2023

Filed:

Jul 18, 2022

Appl. No.:

17/813173

Inventors:

- Basel, CH
Magdalena Alonso-Galicia - Durham NC, US
Thomas Pack - Durham NC, US
Julie Rurka - Raleigh NC, US
David Carpenter - Durham NC, US
Melissa Rhodes - Raleigh NC, US

International Classification:

A61K 31/506
A61P 9/12
A61K 9/00

Abstract:

There is a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day

US Patent:

20200289510, Sep 17, 2020

Filed:

Mar 13, 2020

Appl. No.:

16/818236

Inventors:

- Basel, CH
David Carpenter - Durham NC, US
Thomas Pack - Durham NC, US
Melissa Rhodes - Raleigh NC, US
Julie Rurka - Raleigh NC, US
Steve Wring - South Boston VA, US

International Classification:

A61K 31/506
A61K 9/00
A61P 9/12

Abstract:

There is a method of treating or preventing pulmonary arterial hypertension (PAH) or associated pulmonary arterial hypertension (APAH) in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing PAH or APAH in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day. There is a method for treating PAH or APAH in a patient with a single daily dose.

US Patent:

20200155552, May 21, 2020

Filed:

Nov 15, 2019

Appl. No.:

16/685165

Inventors:

- Basel, CH
Magdalena ALONSO-GALICIA - Durham NC, US
Thomas PACK - Durham NC, US
Julie RURKA - Raleigh NC, US
David CARPENTER - Durham NC, US
Melissa RHODES - Raleigh NC, US

Assignee:

ALTAVANT SCIENCES GmbH - BASEL

International Classification:

A61K 31/506
A61K 9/00
A61P 9/12

Abstract:

There is a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day